Wegovy weight loss at 3 months: a realistic picture

You're three months in and wondering if this is working

Picture this: you started Wegovy at 0.25mg, moved to 0.5mg a month later, and you're now somewhere around the 1mg mark. The number on the scales has moved (maybe 5kg, maybe 8kg) but your friend who started the same week seems to be doing better. You're wondering whether something is wrong.

Nothing is wrong. Three months into Wegovy treatment, almost everyone is still mid-titration, and the dose you are currently on is almost certainly not the maintenance dose you will eventually reach. The 68-week STEP 1 trial published in the New England Journal of Medicine followed adults on 2.4mg semaglutide; participants were still climbing the dose ladder at week 12, and their results at that point were a fraction of what came later. The final average reduction of around 15% took the full study period to accumulate.

Body weight also doesn't follow a straight line. Most people lose more in the first few weeks (partly fluid and appetite shift), then hit a slower middle patch that can feel discouraging. That plateau is not a signal that treatment has stopped working. It is worth tracking the trend over several weeks rather than reacting to day-to-day fluctuations.

If you want to see how the month-by-month picture typically unfolds, our Wegovy weight loss by month breakdown maps the trajectory in more detail.

Why your 3-month result looks different from the clinical trial numbers

The trial figure of roughly 6% at 12 weeks is an average across a large group of people. Real-world variation is wide. Factors that genuinely affect the rate of loss include starting body weight (those with more to lose often lose faster initially), metabolic history, how well gastrointestinal side effects have been managed, and whether activity and eating habits have shifted alongside treatment.

One misconception worth clearing up gently: Wegovy does not work the same way in everyone because appetite suppression is a biological response, not a guarantee. Some people notice a profound change in hunger from the very first dose, and if you are curious about what that earliest period on Wegovy typically delivers in terms of weight loss, the picture can help set realistic expectations before results build. Both early and slower responses are within the normal range seen in trials.

Licensed for adults with a BMI of 30 or above (or 27 or above with a weight-related condition such as high blood pressure or type 2 diabetes), Wegovy is only prescribed after a clinical assessment confirms it is appropriate. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance. For a fuller picture of eligibility criteria and what the assessment involves, the Wegovy overview page covers this in detail.

The NHS semaglutide medicines page also sets out clearly what patients can expect from treatment and what to monitor during it.

Side effects at the three-month mark and what tends to shift

Nausea, loose stools, constipation and indigestion are most common during dose increases. By the three-month point, many people find the worst of it has already passed, or at least settled into something manageable. Each new dose step can bring a brief return of symptoms, particularly the jump to 1.7mg and then 2.4mg, but the body's adjustment period is typically measured in days rather than weeks.

Staying well-hydrated matters a lot here. Reduced appetite can make it easy to forget to drink enough, and dehydration amplifies nausea. Smaller meals, lower-fat options and avoiding lying down after eating are all practical steps that help during titration. None of this replaces the guidance in the Patient Information Leaflet that comes with your pen, or the advice of your prescriber, but they are the kind of things people wish they had been told upfront.

If you are earlier in the journey and want to understand what the first month looks like before reaching this point, the weight loss after one month on Wegovy page covers that ground. For a longer view, Wegovy results at 6 months gives a sense of where most people have reached once the maintenance dose is established.

What actually moves the needle between now and month six

The prescriber's review at each repeat is not a formality. It is the point at which dose progression is assessed, side effects are considered, and the plan is adjusted if needed. This is one reason clinical oversight matters throughout treatment, not just at the start.

Protein intake, strength-based activity and consistent habits around meals tend to separate people who sustain results from those who stall. Wegovy reduces appetite substantially; it does not choose which calories are cut. People who use that appetite reduction to improve food quality alongside quantity tend to do better over the full treatment period.

If you are weighing up the ongoing costs of private treatment, the Wegovy cost context page breaks down what drives pricing in the UK and what a legitimate private prescription typically includes. For those considering whether to start, a free consultation with our prescribers is the first step, they review your answers the same day, and there is no obligation.